REGENXBIO Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
REGENXBIO Inc. (RGNX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $5.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-05
- REGENXBIO Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $5.38M, a 69.82% increase from fiscal 2024.
- REGENXBIO Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $3.17M, a 5.29% decline from fiscal 2023.
- REGENXBIO Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $3.35M, a 4.10% increase from fiscal 2022.
- REGENXBIO Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $3.22M, a 325.96% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $5.38M 10-K · filed 2026-03-05 |
| 2024-12-31 | $3.17M 10-K · filed 2026-03-05 |
| 2023-12-31 | $3.35M 10-K · filed 2025-03-13 |
| 2022-12-31 | $3.22M 10-K · filed 2025-03-13 |
| 2021-12-31 | $755.00K 10-K · filed 2024-02-27 |
| 2020-12-31 | $587.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | -$2.13M 10-K · filed 2022-03-01 |
| 2018-12-31 | -$6.49M 10-K · filed 2021-03-01 |
| 2017-12-31 | -$3.01M 10-K · filed 2020-02-26 |
| 2016-12-31 | $1.80M 10-K · filed 2019-02-27 |
| 2015-12-31 | $283.00K 10-K · filed 2018-03-06 |
| 2014-12-31 | $98.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |